RecruitingPhase 3NCT06345729

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS ≥50% (KANDLELIT-004)

Sponsor

Merck Sharp & Dohme LLC

Enrollment

600 participants

Start Date

May 24, 2024

Study Type

INTERVENTIONAL

Conditions

Non-small Cell Lung Cancer

Summary

This is a study evaluating the efficacy and safety of calderasib with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses: Hypothesis 1: Combination of calderasib and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). Hypothesis 2: Combination of calderasib plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial tests a new targeted drug called calderasib (MK-1084) combined with pembrolizumab (an immunotherapy drug) as a first treatment for people with a specific type of advanced lung cancer. The cancer must have a mutation called KRAS G12C and a high level of a protein (PD-L1) that the immune system can target. **You may be eligible if...** - You have been diagnosed with non-small cell lung cancer (NSCLC) - Your cancer has the KRAS G12C genetic mutation, confirmed by tumor testing - Your cancer expresses high levels of PD-L1 (TPS ≥50%), confirmed by biopsy - Your cancer is at an advanced or metastatic stage (stage IIIB/IIIC or stage IV) and cannot be cured by surgery or standard chemoradiation - You have not yet received treatment for your advanced cancer **You may NOT be eligible if...** - Your tumor does not have the KRAS G12C mutation or does not have high PD-L1 expression - You have already received treatment for advanced-stage lung cancer - You have active autoimmune disease or require immune-suppressing medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCalderasib

Oral tablets

OTHERPlacebo

Oral tablets

BIOLOGICALPembrolizumab

IV infusion

Locations(215)

CBCC Global Research, Inc. ( Site 0123)

Bakersfield, California, United States

Beverly Hills Cancer Center ( Site 0116)

Beverly Hills, California, United States

Stamford Hospital ( Site 0136)

Stamford, Connecticut, United States

Mount Sinai Cancer Center ( Site 0137)

Miami Beach, Florida, United States

Orchard Healthcare Research Inc. ( Site 0115)

Skokie, Illinois, United States

Truman Medical Center ( Site 0126)

Kansas City, Missouri, United States

Cox Medical Center North ( Site 0133)

Springfield, Missouri, United States

St. Vincent Frontier Cancer Center-Research ( Site 0105)

Billings, Montana, United States

Atlantic Health System Morristown Medical Center ( Site 0121)

Morristown, New Jersey, United States

New York Oncology Hematology, P.C. ( Site 0132)

Albany, New York, United States

University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)

Cincinnati, Ohio, United States

Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)

Kettering, Ohio, United States

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)

Lancaster, Pennsylvania, United States

Oncology Consultants P.A. ( Site 0113)

Houston, Texas, United States

Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)

Madison, Wisconsin, United States

AUSTRAL MEDICAL CENTER ( Site 0302)

CABA, Buenos Aires, Argentina

Centro Oncologico Korben ( Site 0304)

CABA, Buenos Aires, Argentina

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)

Mar del Plata, Buenos Aires, Argentina

Fundacion Estudios Clinicos ( Site 0306)

Rosario, Santa Fe Province, Argentina

Sanatorio Parque ( Site 0301)

Rosario, Santa Fe Province, Argentina

Chris O'Brien Lifehouse ( Site 3000)

Camperdown, New South Wales, Australia

Frankston Hospital ( Site 3002)

Frankston, Victoria, Australia

One Clinical Research ( Site 3001)

Nedlands, Western Australia, Australia

Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)

Graz, Styria, Austria

Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)

Vienna, Austria

Hospital Mario Penna ( Site 0436)

Belo Horizonte, Minas Gerais, Brazil

Hospital de Câncer de Recife ( Site 0447)

Recife, Pernambuco, Brazil

Oncoclínica Oncologistas Associados ( Site 0441)

Teresina, Piauí, Brazil

Liga Norte Riograndense Contra o Câncer ( Site 0439)

Natal, Rio Grande do Norte, Brazil

Hospital de Caridade de Ijuí ( Site 0438)

Ijuí, Rio Grande do Sul, Brazil

Hospital de Clínicas de Passo Fundo ( Site 0442)

Passo Fundo, Rio Grande do Sul, Brazil

Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)

Porto Alegre, Rio Grande do Sul, Brazil

Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)

Barretos, São Paulo, Brazil

Instituto Nacional de Câncer - INCA ( Site 0446)

Rio de Janeiro, Brazil

Americas ( Site 0431)

Rio de Janeiro, Brazil

MBAL Uni Hospital-Department of Medical Oncology ( Site 1000)

Panagyurishte, Pazardzhik, Bulgaria

Multiprofile Hospital for Active Treatment SerdikaМЕD EOOD-Second Department of Medical Oncology ( Site 1002)

Sofia, Sofia (stolitsa), Bulgaria

MHAT - Heart and Brain ( Site 1006)

Pleven, Bulgaria

CancerCare Manitoba ( Site 0210)

Winnipeg, Manitoba, Canada

QEII Health Sciences Centre - Victoria General Site-Dept. of Medical Oncology ( Site 0208)

Halifax, Nova Scotia, Canada

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205)

Hamilton, Ontario, Canada

Sunnybrook Research Institute ( Site 0206)

Toronto, Ontario, Canada

St. Marys Hospital Center ( Site 0204)

Montreal, Quebec, Canada

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207)

Trois-Rivières, Quebec, Canada

Clinica Universidad Catolica del Maule-Oncology ( Site 0500)

Talca, Maule Region, Chile

Orlandi Oncologia-Oncology ( Site 0503)

Santiago, Region M. de Santiago, Chile

FALP-UIDO ( Site 0501)

Santiago, Region M. de Santiago, Chile

Centro de Oncología de Precisión-Oncology ( Site 0502)

Santiago, Region M. de Santiago, Chile

Bradfordhill-Clinical Area ( Site 0504)

Santiago, Region M. de Santiago, Chile

Anhui Provincial Cancer Hospital ( Site 3136)

Hefei, Anhui, China

Beijing Cancer hospital ( Site 3133)

Beijing, Beijing Municipality, China

Beijing Cancer hospital ( Site 3134)

Beijing, Beijing Municipality, China

Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102)

Beijing, Beijing Municipality, China

Beijing Chest Hospital,Capital Medical University ( Site 3104)

Beijing, Beijing Municipality, China

Chongqing University Cancer Hospital ( Site 3119)

Chongqing, Chongqing Municipality, China

Army Medical Center of People's Liberation Army ( Site 3142)

Chongqing, Chongqing Municipality, China

Fujian Cancer Hospital ( Site 3127)

Fuzhou, Fujian, China

The First Affiliated hospital of Xiamen University ( Site 3148)

Xiamen, Fujian, China

The First Affiliated Hospital of Guangzhou Medical University ( Site 3108)

Guangzhou, Guangdong, China

Southern Medical University Nanfang Hospital ( Site 3128)

Guangzhou, Guangdong, China

Sun Yat-sen University Cancer Center ( Site 3137)

Guangzhou, Guangdong, China

Harbin Medical University Cancer Hospital ( Site 3123)

Harbin, Heilongjiang, China

JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124)

Jiamusi, Heilongjiang, China

Henan Cancer Hospital ( Site 3149)

Zhengzhou, Henan, China

Tongji Hospital Tongji Medical,Science & Technology ( Site 3113)

Wuhan, Hubei, China

Hubei Cancer Hospital ( Site 3126)

Wuhan, Hubei, China

The Second Xiangya Hospital of Central South University ( Site 3130)

Changsha, Hunan, China

Hunan Cancer Hospital ( Site 3141)

Changsha, Hunan, China

Nanjing Gulou Hospital ( Site 3122)

Nanjing, Jiangsu, China

Nanjing First Hospital ( Site 3154)

Nanjing, Jiangsu, China

The First Affiliated Hospital of Soochow University ( Site 3146)

Suzhou, Jiangsu, China

Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155)

Wuxi, Jiangsu, China

The Second Affiliated Hospital of Nanchang University ( Site 3139)

Nanchang, Jiangxi, China

The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138)

Nanchang, Jiangxi, China

Jilin Province Tumor Hospital ( Site 3107)

Changchun, Jilin, China

The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150)

Xi'an, Shaanxi, China

Shandong Cancer Hospital ( Site 3116)

Jinan, Shandong, China

LinYi Cancer Hospital ( Site 3111)

Linyi, Shandong, China

Shanghai Chest Hospital ( Site 3100)

Shanghai, Shanghai Municipality, China

Fudan University Shanghai Cancer Center ( Site 3144)

Shanghai, Shanghai Municipality, China

Zhongshan Hospital,Fudan University ( Site 3143)

Shanghai, Shanghai Municipality, China

Shanxi Cancer Hospital ( Site 3131)

Taiyuan, Shanxi, China

The Second Affiliated Hospital of Air Force Medical University ( Site 3117)

Xian, Shanxi, China

The Second Affiliated Hospital of Air Force Medical University ( Site 3152)

Xian, Shanxi, China

West China Hospital, Sichuan University ( Site 3140)

Chengdu, Sichuan, China

The Third People's Hospital of Chengdu (CDTPH) ( Site 3157)

Chengdu, Sichuan, China

Sichuan Cancer hospital. ( Site 3109)

Chengdu, Sichuan, China

The Second People's Hospital of Neijiang ( Site 3105)

Neijiang, Sichuan, China

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101)

Ürümqi, Xinjiang, China

Yunnan Province Cancer Hospital ( Site 3153)

Kunming, Yunnan, China

The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)

Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121)

Hangzhou, Zhejiang, China

Taizhou Hospital of Zhejiang Province ( Site 3145)

Linhai, Zhejiang, China

The First Affiliated Hospital of Wenzhou Medical University ( Site 3151)

Wenzhou, Zhejiang, China

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1103)

Dijon, Bourgogne-Franche-Comté, France

Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 1106)

Nîmes, Gard, France

Clinique Teissier Groupe ( Site 1100)

Valenciennes, Nord, France

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101)

Clermont-Ferrand, Puy-de-Dome, France

Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1104)

Avignon, Vaucluse, France

Hôpital Ambroise Paré-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105)

Boulogne-Billancourt, Île-de-France Region, France

High Technology Hospital Medcenter ( Site 1203)

Batumi, Adjara, Georgia

Caucasus Medical Centre ( Site 1202)

Tbilisi, Adjara, Georgia

American Hospital Network LLC ( Site 1208)

Tbilisi, Georgia

Todua Clinic, LLC ( Site 1204)

Tbilisi, Georgia

TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201)

Tbilisi, Georgia

New Hospitals ( Site 1200)

Tbilisi, Georgia

Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205)

Tbilisi, Georgia

Tbilisi Institute of Medicine ( Site 1206)

Tbilisi, Georgia

Marienhospital Stuttgart ( Site 1302)

Stuttgart, Baden-Wurttemberg, Germany

Evangelisches Krankenhaus Bielefeld - Johannesstift ( Site 1307)

Bielefeld, North Rhine-Westphalia, Germany

Krankenhaus Bethanien ( Site 1303)

Solingen, North Rhine-Westphalia, Germany

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402)

Pátrai, Achaia, Greece

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400)

Athens, Attica, Greece

Athens Medical Center ( Site 1406)

Marousi, Attica, Greece

University General Hospital of Larissa-Oncology Clinic ( Site 1403)

Larissa, Thessaly, Greece

Agios Loukas Clinic ( Site 1404)

Thessaloniki, Greece

G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405)

Thessaloniki, Greece

Sir H. N. Reliance Foundation Hospital and Research Centre ( Site 3201)

Mumbai, Maharashtra, India

Indraprastha Apollo Hospitals-APOLLO RESEARCH INNOVATION ( Site 3203)

New Delhi, National Capital Territory of Delhi, India

Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607)

Naples, Campania, Italy

Ospedale Santa Maria delle Croci ( Site 1606)

Ravenna, Emilia-Romagna, Italy

CRO-IRCCS-Clinical Oncology ( Site 1605)

Aviano, Friuli Venezia Giulia, Italy

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601)

Rome, Lazio, Italy

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1600)

Milan, Lombardy, Italy

Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604)

Milan, Lombardy, Italy

A.O.R.N. Ospedale dei Colli - Monaldi V.-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1602)

Naples, Napoli, Italy

Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609)

Rome, Roma, Italy

Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608)

Livorno, Tuscany, Italy

IOV - Istituto Oncologico Veneto IRCCS UOSD - Unità di ricerca clinica ( Site 1603)

Padova, Italy

Nagoya University Hospital ( Site 3309)

Nagoya, Aichi-ken, Japan

Fujita Health University Hospital ( Site 3310)

Toyoake, Aichi-ken, Japan

National Cancer Center Hospital East ( Site 3303)

Kashiwa, Chiba, Japan

National Hospital Organization Shikoku Cancer Center ( Site 3315)

Matsuyam, Ehime, Japan

National Hospital Organization Kyushu Cancer Center ( Site 3316)

Fukuoka, Fukuoka, Japan

Kurume University Hospital ( Site 3317)

Kurume, Fukuoka, Japan

Gunma Prefectural Cancer Center ( Site 3302)

Ōta, Gunma, Japan

Sapporo Medical University Hospital ( Site 3324)

Sapporo, Hokkaido, Japan

Kanazawa University Hospital ( Site 3308)

Kanazawa, Ishikawa-ken, Japan

St. Marianna University Hospital ( Site 3320)

Kawasaki, Kanagawa, Japan

Saiseikai Matsusaka Municipal Hospital ( Site 3311)

Matsusaka, Mie-ken, Japan

Miyagi Cancer Center ( Site 3301)

Natori-shi, Miyagi, Japan

Sendai Kousei Hospital ( Site 3300)

Sendai, Miyagi, Japan

Kansai Medical University Hospital ( Site 3312)

Hirakata, Osaka, Japan

Osaka Medical and Pharmaceutical University Hospital ( Site 3313)

Takatsuki, Osaka, Japan

Saitama Prefectural Cancer Center ( Site 3304)

Kitaadachi-gun, Saitama, Japan

Nippon Medical School Hospital ( Site 3306)

Bunkyo, Tokyo, Japan

Toho University Omori Medical Center ( Site 3319)

Ōta-ku, Tokyo, Japan

Tokyo Medical University Hospital ( Site 3307)

Shinjuku, Tokyo, Japan

National Center for Global Health and Medicine ( Site 3305)

Shinjuku, Tokyo, Japan

Chiba University Hospital ( Site 3322)

Chiba, Japan

Hiroshima City Hiroshima Citizens Hospital ( Site 3314)

Hiroshima, Japan

Saiseikai Kumamoto Hospital ( Site 3318)

Kumamoto, Japan

Niigata University Medical & Dental Hospital ( Site 3323)

Niigata, Japan

Osaka Metropolitan University Hospital ( Site 3321)

Osaka, Japan

Arké SMO S.A. de C.V. ( Site 0602)

Mexico City, Mexico City, Mexico

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0600)

Monterrey, Nuevo León, Mexico

Oaxaca Site Management Organization S.C. ( Site 0603)

Oaxaca City, Mexico

Ziekenhuis Gelderse Vallei ( Site 1705)

Ede, Gelderland, Netherlands

Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701)

Harderwijk, Gelderland, Netherlands

Isala, locatie Zwolle-Poli Longziekten ( Site 1700)

Zwolle, Overijssel, Netherlands

Universitair Medisch Centrum Utrecht ( Site 1704)

Utrecht, Netherlands

Auckland City Hospital ( Site 3400)

Auckland, New Zealand

The Medical City ( Site 3507)

Pasig, National Capital Region, Philippines

Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503)

Quezon City, National Capital Region, Philippines

Veterans Memorial Medical Center-Section of Oncology ( Site 3505)

Quezon City, National Capital Region, Philippines

ST. LUKE'S MEDICAL CENTER-Medical oncology ( Site 3501)

Quezon City, National Capital Region, Philippines

Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1801)

Gorlice, Lesser Poland Voivodeship, Poland

Pratia MCM Krakow ( Site 1808)

Krakow, Lesser Poland Voivodeship, Poland

Uniwersytecki Szpital Kliniczny nr 4 w Lublinie ( Site 1805)

Lublin, Lublin Voivodeship, Poland

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1800)

Warsaw, Masovian Voivodeship, Poland

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1804)

Przemyśl, Podkarpackie Voivodeship, Poland

Centrul de Diagnostic si Tratament Provita. ( Site 1992)

Bucharest, Bucharest, Romania

Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994)

Craiova, Dolj, Romania

Cabinet Medical Oncomed ( Site 1998)

Timișoara, Timiș County, Romania

SC ONCO CARD SRL ( Site 1995)

Brasov, Romania

Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999)

Cluj-Napoca, Romania

Sigmedical Services SRL ( Site 1997)

Suceava, Romania

The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606)

Bupyeong-gu, Incheon, South Korea

Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604)

Hwasun, Jeonranamdo, South Korea

The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600)

Suwon, Kyonggi-do, South Korea

Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603)

Yangsan, Kyongsangnam-do, South Korea

Keimyung University Dongsan Hospital ( Site 3611)

Daegu, Taegu-Kwangyokshi, South Korea

Chungnam national university hospital ( Site 3602)

Junggu, Taejon-Kwangyokshi, South Korea

Kyung Hee University Hospital ( Site 3605)

Seoul, South Korea

The Catholic University of Korea, Eunpyeong St. Mary's Hospital ( Site 3608)

Seoul, South Korea

Korea University Guro Hospital ( Site 3601)

Seoul, South Korea

Hospital Universitario Virgen de la Victoria ( Site 2021)

Málaga, Andalusia, Spain

Hospital Insular de Gran Canaria-Oncology ( Site 2019)

Las Palmas de Gran Canaria, Las Palmas, Spain

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2012)

Madrid, Madrid, Comunidad de, Spain

H.R.U Málaga - Hospital General-Oncology ( Site 2014)

Málaga, Malaga, Spain

Hospital Universitari Vall d Hebron ( Site 2010)

Barcelona, Spain

Hospital Universitario La Princesa ( Site 2020)

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2017)

Madrid, Spain

Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2015)

Seville, Spain

Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2102)

Bornova, İzmir, Turkey (Türkiye)

Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107)

Adana, Turkey (Türkiye)

SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104)

Ankara, Turkey (Türkiye)

Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101)

Ankara, Turkey (Türkiye)

Memorial Ankara Hastanesi-Medical Oncology ( Site 2106)

Ankara, Turkey (Türkiye)

Ankara Bilkent Şehir Hastanesi ( Site 2100)

Ankara, Turkey (Türkiye)

Medipol Mega Universite Hastanesi-oncology ( Site 2105)

Istanbul, Turkey (Türkiye)

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2103)

Istanbul, Turkey (Türkiye)

COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209)

Cherkasy, Cherkasy Oblast, Ukraine

Regional Municipal Non-profit Enterprise "Bukovinian Clinica-structural unit of the clinical trials ( Site 2210)

Chernivtsi, Chernivetska Oblast, Ukraine

Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2215)

Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine

Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 2202)

Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204)

Kropyvnytskyi, Kirovohrad Oblast, Ukraine

Medical Center "MedOffice Group" ( Site 2219)

Kiev, Kyivska Oblast, Ukraine

Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 2217)

Lviv, Lviv Oblast, Ukraine

Rivne Regional Clinical Hospital ( Site 2205)

Rivne, Rivne Oblast, Ukraine

ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2920)

Rivne, Rivne Oblast, Ukraine

Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 2211)

Vinnytsia, Vinnytsia Oblast, Ukraine

ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216)

Lutsk, Volyn Oblast, Ukraine

Milton Keynes Hospital ( Site 2304)

Milton Keynes, Buckinghamshire, United Kingdom

Royal Devon & Exeter Hospital-Oncology ( Site 2302)

Exeter, Devon, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06345729

Related Trials

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

NCT0621891418 locations

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738301 locations

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT0606804925 locations

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386299 locations

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT0614703715 locations